NCT06567743ClinicalTrials.gov

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.

Contatta questo studio

In breve

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.

Fase 2325 partecipanti ricercati80 centri2 paesi

Categorie

Oncologia52%Nefrologia e urologia39%Ostetricia e ginecologia9%

Registrato in 1 registro

ClinicalTrials.govNCT06567743Apri questa scheda su ClinicalTrials.govSincronizzato 3 settimane fa

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2024-08-23; recorded start 2024-09-16
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Not stated: Open label (no blinding)Masking is recorded as none (open label)
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 3 other studies in this databaseCounted from the lead sponsor named in the record (CG Oncology, Inc.)
Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourMODERATE

A moderately rigorous design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding0/20
Open-label
Control arm0/15
No comparator arm stated in the record
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 65 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 325 participants (target), run at 80 sites, across 2 countries.

How this score is built

Enrolment24/40
325 participants (target)
Site count21/25
65 sites
Country count0/15
Single country
Planned duration8/10
Planned over about 40 months
Sponsor scale2/10
CG Oncology, Inc. has led 4 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.

In Cohort A, up to 125 participants will be enrolled with pathologically confirmed, high-risk high-grade non-muscle invasive bladder cancer (NMIBC) NMIBC (i.e., CIS with or without concomitant Ta or T1 disease OR HG Ta/T1 disease without CIS) which is naïve to Bacillus Calmette-Guerin (BCG) treatment. Participants with CIS with or without concomitant Ta/T1 NMIBC at baseline will be randomized 1:1 to receive cretostimogene via the current (Arm 1) or an alternative instillation procedure (Arm 2). Participants with papillary-only high-risk NMIBC (i.e., HG Ta/T1 without CIS) at baseline (Arm 3) will receive cretostimogene via the alternative instillation procedure. In Cohort B, up to 150 participants will be enrolled with pathologically confirmed, high-risk high-grade NMIBC (i.e., CIS with or without concomitant Ta or T1 disease OR HG Ta/T1 disease without CIS) which has previously been exposed to BCG treatment. Participants with CIS-containing pathology at baseline will be recruited into Arm 1 and participants with papillary-only pathology at baseline will be recruited into Arm 2. Both Cohort B Arms 1 and 2 will receive cretostimogene via the alternative instillation procedure. In Cohort CX, up to 50 participants will be enrolled with pathologically confirmed, high-risk high-grade NMIBC (i.e., CIS with or without concomitant Ta or T1 disease OR HG Ta/T1 disease without CIS) which has previously been exposed to or is unresponsive to BCG treatment. Participants will be randomized 1:1 to receive cretostimogene and gemcitabine either concurrently or sequentially. In all cohorts, study treatment will be administered as a weekly induction course for the first 6 weeks with a reinduction course administered to patients who have CIS and/or high-grade Ta disease at the 3-month evaluation. Following induction, if no high-grade disease is detected, maintenance treatment will begin. This consists of a cycle of three weekly treatments every three months during the first year, and every six months during the second year, with an optional extension to the third year following the same six-month schedule. Disease status will be assessed using urine cytology, complete bladder visualization (e.g., cystoscopy), upper tract assessment and directed resection/biopsy (if indicated) every 3 months for the first 2 years and then every 6 months for a further 2 years or until disease recurrence.

Patologie

High-Risk Non-Muscle-Invasive Bladder Cancer

Idoneità

Idoneità
Sesso	Tutti
Età	18 Years – Nessun massimo
Volontari sani	No

Idoneità come riportata nel registro

Cohort A Key Inclusion Criteria: * Pathologically confirmed BCG-naïve high-risk high-grade NMIBC (i.e., CIS with or without Ta/T1 disease or high-grade Ta/T1 papillary-only disease without CIS) within 90 days of treatment allocation. * All visible disease must be resected, and all CIS resected or fulgurated, as feasible within 90 days prior to treatment allocation. * Acceptable baseline organ function. Cohort B Key Inclusion Criteria: * Pathologically confirmed BCG-exposed high-risk high-grade NMIBC (i.e., CIS with or without Ta/T1 disease or high-grade Ta/T1 papillary-only disease without CIS) within 90 days of treatment allocation. * All visible disease must be resected, and all CIS resected or fulgurated, as feasible within 90 days prior to treatment allocation. * Acceptable baseline organ function. Cohort CX Inclusion Criteria * Pathologically confirmed high-risk high-grade BCG-unresponsive or BCG-exposed NMIBC (i.e., CIS with or without Ta/T1 disease or high-grade Ta/T1 papillary-only disease without CIS) within 90 days of treatment allocation. * All visible disease must be resected, and all CIS resected or fulgurated, as feasible within 90 days prior to treatment allocation. * Acceptable baseline organ function. Key Exclusion Criteria (Both Cohorts): * Current or past history of muscle-invasive, locally advanced or metastatic bladder cancer. * High-grade urothelial carcinoma in the upper urinary tract or prostatic urethra within 24 months or T2 in upper tract within 48 months or any history of locally advanced/ nodal or metastatic disease in the upper urinary tract. * Significant immunodeficiency. * Pregnant or breastfeeding. * Cohort CX Only: serial intravesical gemcitabine within 24 months

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studio	Interventistico
Fase	Fase 2
Assegnazione	Randomizzata
Modello di intervento	PARALLEL
Finalità principale	TREATMENT
Mascheramento	NONE (0)
Arruolamento	325 partecipanti ricercati

Sponsor e collaboratori

CG Oncology, Inc. Sponsor

Bracci e interventi

Experimental: Cohort A, Arm 1EXPERIMENTAL
Cretostimogene (1 x 1012 vp) will be administered intravesically via the current instillation method
Experimental: Cohort A, Arm 2EXPERIMENTAL
Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.
Experimental: Cohort A, Arm 3EXPERIMENTAL
Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.
Experimental: Cohort B, Arm 1EXPERIMENTAL
Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.
Experimental: Cohort B, Arm 2EXPERIMENTAL
Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.
Experimental: Cohort CX, Arm 1EXPERIMENTAL
At all treatment visits cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method followed by gemcitabine instilled intravesically
Experimental: Cohort CX, Arm 2EXPERIMENTAL
Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method for two consecutive weeks, followed by gemcitabine administered intravesically in the third week on a cyclic 2:1 visit schedule basis

Interventi

Farmaco Cretostimogene Grenadenorepvec
Respective Cohort

Esiti misurati

Esito primario
Cohort A (Arm 1 and 2): Complete response rate
Determine the complete response rate at any time following treatment with cretostimogene in participants with BCG-naïve CIS with or without concomitant high-grade Ta or T1 disease at baseline
Orizzonte temporale At 11 and 24 weeks
Esito primario
Cohort A (Arm 3): High- Grade Event-Free Survival
Determine the High-Grade Event-Free Survival following treatment with cretostimogene in participants with BCG-naïve HG Ta/T1 disease without concomitant CIS at baseline.
Orizzonte temporale 48 months
Esito primario
Cohort B (Arm 1): Complete response rate
Determine the complete response rate at any time following treatment with cretostimogene in participants with BCG-exposed CIS with or without concomitant high-grade Ta or T1 disease at baseline.
Orizzonte temporale At 11 and 24 weeks
Esito primario
Cohort B (Arm 2): High-Grade Event-Free Survival
Determine the High-Grade Event-Free Survival following treatment with cretostimogene in participants with BCG-exposed high-grade Ta/T1 papillary disease without CIS at baseline.
Orizzonte temporale 48 months
Esito primario
Cohort CX (Arms 1 and 2): High-Grade Event-Free Survival
Determine the High-Grade Event-Free Survival following treatment with cretostimogene in participants with BCG-exposed or BCG-unresponsive high-grade NMIBC.
Orizzonte temporale 48 months
Esito primario
Cohort CX (Arms 1 and 2): Safety
Determine the safety of concurrent cretostimogene and gemcitabine and sequential cretostimogene and gemcitabine.
Orizzonte temporale 48 months
Esito secondario
Cohort A (Arms 1 and 2): Evaluate cretostimogene instillation methods
Evaluate cretostimogene genome and GM-CSF levels, treatment efficacy, and safety by 2 different methods of cretostimogene instillation in participants with pathologically confirmed CIS-containing high-risk NMIBC who are naïve to BCG treatment.
Orizzonte temporale At 11 and 24 weeks
Esito secondario
Cohort A (Arm 3): High-Grade Event-Free Survival at 12 months
Determine the proportion of participants with BCG-naive papillary-only high-grade NMIBC at baseline who are free from high-grade events at 12 months
Orizzonte temporale At 12 months
Esito secondario
Cohort A (Arms 1 and 2) and Cohort B (Arm 1) Duration of response
Assess duration of response in participants with CIS with or without concomitant HG Ta/T1 disease at baseline
Orizzonte temporale 48 months
Esito secondario
Cohort B (Arm 2) High-Grade Event-Free Survival at 12 months
Determine the proportion of participants with BCG-exposed papillary-only high-grade NMIBC at baseline who are free from high-grade events at 12 months
Orizzonte temporale At 12 months
Esito secondario
Cohort CX (Arm 1 and 2) Complete response rate
Determine the complete response rate at any time following treatment with cretostimogene and gemcitabine in participants with BCG-exposed or BCG-unresponsive CIS with or without concomitant high-grade Ta or T1 disease at baseline.
Orizzonte temporale At 11 and 24 weeks

Date

Date
Data di inizio	16 settembre 2024 (effettiva)
Conclusione primaria	31 marzo 2027 (stimata)
Conclusione	30 dicembre 2027 (stimata)
Prima pubblicazione	23 agosto 2024 (effettiva)
Ultimo aggiornamento	3 settembre 2026
Risultati pubblicati	Non indicato nella scheda del registro
Stato verificato l'ultima volta	settembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

76 centri stanno reclutando

Canada

Canada
Struttura	Città	Stato o regione	Stato
Centre of Applied Urology Research Nova Scotia Health Authority	Halifax	Nova Scotia	In reclutamento

United States

United States
Struttura	Città	Stato o regione	Stato
Potomac Urology	Alexandria	Virginia	In reclutamento
Amarillo Urology Research	Amarillo	Texas	Completato
Anne Arundel Urology	Annapolis	Maryland	In reclutamento
UPNT Research Institute, LLC	Arlington	Texas	In reclutamento
Emory University	Atlanta	Georgia	In reclutamento
Urology Austin, PLLC (Urology America)	Austin	Texas	In reclutamento
Michael G Oefelein, MD Clinical Trials	Bakersfield	California	In reclutamento
Midlantic Urology (Solaris)	Bala-Cynwyd	Pennsylvania	In reclutamento
Brigham and Women's Hospital	Boston	Massachusetts	In reclutamento
Urology of Indiana - Carmel	Carmel	Indiana	In reclutamento
University of North Carolina	Chapel Hill	North Carolina	In reclutamento
Charleston Area Medical Center	Charleston	South Carolina	In reclutamento
Atrium Health/Levine Center	Charlotte	North Carolina	In reclutamento
Associated Urological Specialists	Chicago Ridge	Illinois	In reclutamento
The Urology Group (Solaris)	Cincinnati	Ohio	In reclutamento
University of Cincinnati Cancer Center	Cincinnati	Ohio	In reclutamento
Cleveland Clinic	Cleveland	Ohio	In reclutamento
Urology Center of Iowa Research	Clive	Iowa	In reclutamento
Ohio State University	Columbus	Ohio	In reclutamento
UT Southwestern Medical Center	Dallas	Texas	In reclutamento
Urology Clinics of North Texas, PLLC	Dallas	Texas	In reclutamento
Central Ohio Urology Group (US Urology Partners)	Gahanna	Ohio	In reclutamento
University of Florida	Gainesville	Florida	In reclutamento
The Conrad Pearson Clinic (Urology America)	Germantown	Tennessee	In reclutamento
Banner MD Anderson Cancer Center	Gilbert	Arizona	In reclutamento
Uropartners	Glenview	Illinois	In reclutamento
Urology of Indiana, LLC (US Urology Partners)	Greenwood	Indiana	In reclutamento
Hackensack University Medical Center	Hackensack	New Jersey	In reclutamento
Chesapeake Urology Research Associates	Hanover	Maryland	In reclutamento
Penn State University Milton S. Hershey Medical Center	Hershey	Pennsylvania	In reclutamento
Houston Methodist	Houston	Texas	In reclutamento
City of Hope	Irvine	California	In reclutamento
Mayo Clinic Florida	Jacksonville	Florida	In reclutamento
First Urology, PSC	Jeffersonville	Indiana	In reclutamento
Southern Urology (Urology America)	Lafayette	Louisiana	In reclutamento
Colorado Urology	Lakewood	Colorado	In reclutamento
Keystone Urology Specialists	Lancaster	Pennsylvania	In reclutamento
Advanced Urology Institute (Solaris)	Largo	Florida	In reclutamento
Accellacare	Lisle	Illinois	In reclutamento
University of Arkansas for Medical Sciences	Little Rock	Arkansas	In reclutamento
Arkansas Urology	Little Rock	Arkansas	In reclutamento
Urology Associates, Lone Tree	Lone Tree	Colorado	In reclutamento
Genesis Research (Greater Los Angeles)	Los Alamitos	California	In reclutamento
Advanced Urology	Los Angeles	California	Ritirato
Urologic Specialists of Northwest Indiana (Solaris)	Merrillville	Indiana	In reclutamento
Urology Center of Southern California	Murrieta	California	In reclutamento
Carolina Urologic Research Center, LLC	Myrtle Beach	South Carolina	In reclutamento
Urology Associates, PC	Nashville	Tennessee	In reclutamento
Ochsner Medical Center	New Orleans	Louisiana	In reclutamento

Nella scheda del registro sono indicati altri 30 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

3 settembre 2026
Centro aggiunto
15 sites added (80 total)
6580

Registro: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT06567743